Exhibit 99.1

                                                                  (Logo Omitted)

THERMOGENESIS  AND  MEDTRONIC  SIGN  THROMBIN  PROCESSING  DEVICE(TM)  (TPD(TM))
AGREEMENT

RANCHO CORDOVA,  California  (November 8, 2005) -- ThermoGenesis  Corp. (NASDAQ:
KOOL)  announced  today  that the  Company  has  signed a  worldwide  OEM Supply
Agreement with  Medtronic,  Inc. Under the agreement,  ThermoGenesis  Corp. will
supply its TPD to Medtronic for sale by Medtronic.

Medtronic will be responsible for combining the TPD with their Magellan(R)
Autologous Platelet Separation System, enabling physicians to create an all
"autologous" platelet gel. The TPD disposable kit produces stable, activated
thrombin from the patient's own blood plasma in less than 30 minutes. Medtronic
initially plans to distribute the product supplied by ThermoGenesis for
autologous platelet gels in Europe, Canada, and Asia. Currently, approximately
$50 million/year of bovine thrombin is consumed worldwide in the production of
platelet gels for treatment of damaged tissue.

Kevin Simpson, President & COO of ThermoGenesis noted, "We are pleased to
support Medtronic's Magellan team by supplying the TPD. Markets outside the
United States remain interested in autologous platelet gels in lieu of products
that utilize bovine thrombin. Bovine thrombin has been reported to cause adverse
reactions in patients in 28 peer-reviewed journal articles. In Europe and Japan,
these health risks and additional concerns about "mad cow disease" have nearly
ended the clinical use of bovine thrombin."

ThermoGenesis has been given the right to affix the CE Mark by its Notified
Body. This agreement enables Medtronic to combine TPD product with their
Magellan APS System. In the United States, Medtronic will need to seek PMA
approval to be able to market the platelet gel with the TPD thrombin.

About THERMOGENESIS CORP.
-------------------------
ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics.
The Company's technology platforms lead the world in their ability to produce
biological products from single units of blood.
o        The BioArchive(R) System, an automated robotic cryogenic device, is
         used by major cord blood stem cell banks in 26 countries as a key
         enabling technology for cryopreserving and archiving cord blood stem
         cell units for transplant.
o        The AutoXpress(TM) System, currently undergoing testing, is a
         semi-automated robotic device and companion sterile closed blood
         processing disposable, to harvest stem cells from cord blood.
o        The CryoSeal(R) FS System, a semi-automated device and companion
         sterile blood processing disposable, is used to prepare hemostatic and
         adhesive surgical sealants from the patient's blood in about an hour.
         Enrollment in a 150 patient U.S. pivotal clinical trial has been
         completed and a PMA is being prepared.
o        The Thrombin Processing Device (TPD) is a sterile blood processing
         disposable that prepares activated thrombin from a small aliquot of
         patient blood, or blood plasma in 25 minutes. The TPD market launch is
         underway in Europe.

The  statements  contained in this release  which are not  historical  facts are
forward-looking  statements  that are  subject to risks and  uncertainties  that
could cause  actual  results to differ  materially  from those  expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company's  control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the  Company's  filings  with the  Securities  and Exchange
Commission.

                           More Information, Contact:
                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100